Page 44 - Institutional Equities News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Astral's reported revenue of Rs 1,370.2 crore in the December quarter, up 8 percent from the year-ago period

Policybazaar share price: PB Fintech's first-ever profit catapulted its stock to a fresh 52-week high. Target price upgrades served as the icing on the cake. BofA raised the target, retaining its neutral rating. Kotak Institutional Equities maintained a buy view relying on broad-based growth. Nuvama raised the price target but retained the 'reduce' rating on rich valuations. PB Fintech reported a consolidated net profit of Rs 38 crore, against a loss a year ago. Revenue increased 43% YoY to Rs 871 crore.

Maruti Suzuki Q3 earnings: Motilal Oswal is expecting profit figure at Rs 3,072 crore, up 30.7 per cent YoY. It sees sales climbing 15.2 per cent YoY to Rs 33,471 crore. It sees Ebitda margin at 12.2 per cent.

Sun Pharmaceutical Industries is set to release its Q3 results, with expected moderate earnings growth. Analysts will monitor factors including US business growth, Taro Pharmaceutical's performance, margin trajectory, planned product launches, and R&D investments. Estimated growth in net profit, revenue, and operating profit is also anticipated. The company is expected to see a rise in US revenue, driven by specialty sales. Growth in domestic formulations is projected, and R&D spend will be closely monitored.

Ambuja Cements Q3 results: ICICI Securities sees profit for Ambuja Cements to rise 54 per cent to Rs 568.20 crore on 1.9 per cent fall in sales at Rs 4,049.20 crore. It sees Ebitda margin at 21.1 per cent and Ebitda per tonne at Rs 1,222.